Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.64 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415809 | 1.00 | IDO1 (0.64) | IDO1LOXL2TSHRALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1008784 | 0.98 | IDO1 (0.65) | IDO1LOXL2TSHRALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1922656 | 0.98 | IDO1 (0.65) | IDO1LOXL2TSHRALDH1A1MAPT | |
| SCHEMBL2673969 | 0.82 | LOXL2 (0.59) | IDO1LOXL2TSHRALDH1A1MAPT | |
| SCHEMBL12415781 | 0.82 | IDO1 (0.43) | IDO1LOXL2ALDH1A1MAPTMEN1 | |
| Guanidine SCHEMBL27922792 | 0.81 | TSHR (0.64) | IDO1LOXL2TSHRALDH1A1TDP1 | |
| SCHEMBL12953925 | 0.81 | LOXL2 (0.57) | IDO1LOXL2TSHRALDH1A1MAPT | |
| SCHEMBL6659092 | 0.81 | LOXL2 (0.57) | IDO1LOXL2TSHRALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL11771000 | 0.81 | IDO1 (0.57) | IDO1LOXL2TSHRALDH1A1MAPT | |
| SCHEMBL1829314 | 0.81 | LOXL2 (0.57) | IDO1LOXL2TSHRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3293180-A1 | PROCESS FOR PREPARING [4,6-BIS-DIMETHYLAMINO-2-[4-(4-TRIFLUOROMETHYLBENZOYL-AMINO)BENZYL]PYRIMIDIN-5-YL]ACETIC ACID | Actimis Pharmaceuticals, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-2709988-B1 | PROCESS FOR PREPARING [4,6-BIS-DIMETHYLAMINO-2-[4-(4-TRIFLUOROMETHYLBENZOYL-AMINO)BENZYL]PYRIMIDIN-5-YL]ACETIC ACID | BOEHRINGER INGELHEIM INT (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-8859770-B2 | Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859770-B2 | Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20140187779-A1 | Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20140187779-A1 | Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8541419-B2 | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists | ACTIMIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541419-B2 | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists | ACTIMIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| WO-2012156221-A1 | PROCESS FOR PREPARING [4,6-BIS-DIMETHYLAMINO-2-[4-(4-TRIFLUOROMETHYLBENZOYL-AMINO)BENZYL]PYRIMIDIN-5-YL]ACETIC ACID | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | WO | disclosed |
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | GB005, INC. | 2011-07-14 | — | — | US | disclosed |
| US-7812160-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812160-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2010027448-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTIMIS PHARMACEUTICALS INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| EP-1718649-B1 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | ACTIMIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | ACTIMIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | HRH2, HRH1, HRH4 | IDO1 1237/4885LOXL2 682/4885TSHR 688/4885 |
| US-20140187779-A1 | Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid | AKR7A2, CYP4B1, CYP3A4 | IDO1 840/4885LOXL2 3770/4885TSHR 3614/4885 |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | HRH2, CCR2, HRH1 | IDO1 436/4885LOXL2 554/4885TSHR 954/4885 |
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH4 | IDO1 593/4885LOXL2 955/4885TSHR 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.